lenticas9 blast vector Search Results


lenticas9 blast vector  (New England Biolabs)
99
New England Biolabs lenticas9 blast vector
Lenticas9 Blast Vector, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lenticas9+blast+vector/10__1158_slash_2326___6066__cir___22___0056-119-14-19?v=New+England+Biolabs
Average 99 stars, based on 1 article reviews
lenticas9 blast vector - by Bioz Stars, 2026-08
99/100 stars
  Buy from Supplier
lenticas9 blast vector  (Addgene inc)
96
Addgene inc lenticas9 blast vector
Lenticas9 Blast Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lenticas9+blast+vector/pm31862710-49-1-23?v=Addgene+inc
Average 96 stars, based on 1 article reviews
lenticas9 blast vector - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier
2 vector format  (Addgene inc)
96
Addgene inc 2 vector format
2 Vector Format, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lenticas9+blast+vector/pmc08546599-119-4-16?v=Addgene+inc
Average 96 stars, based on 1 article reviews
2 vector format - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier
lenticas9 blast expression vector  (Addgene inc)
92
Addgene inc lenticas9 blast expression vector
Lenticas9 Blast Expression Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lenticas9+blast+vector/bio_rxiv__2021__06__17__448773-164-7-12?v=Addgene+inc
Average 92 stars, based on 1 article reviews
lenticas9 blast expression vector - by Bioz Stars, 2026-08
92/100 stars
  Buy from Supplier
constitutive cas9 vectors  (Addgene inc)
96
Addgene inc constitutive cas9 vectors
Figure 2. TDI-11055 suppresses the cellular growth of MLL-r and NPM1-mutated leukemia cells through on-target inhibition of ENL. A and B, Dose– response viability curves (8 days) for TDI-11055 in human leukemia cell lines with high (A) and low (B) dependence on ENL defined by genetic studies. n = 3. NPM1 mut, NPM1-mutated. C–F, Representative images (left) and quantification (right) of colonies formed by indicated human leukemia cell lines treated with DMSO or TDI-11055 (TDI; 1 and 10 μmol/L). Error bars represent mean ± SEM (n = 3). One of two independent experiment batches is shown. G, Schematic of <t>CRISPR-Cas9</t> mutagenesis scanning workflow. MOI, multiplicity of infection; sgRNA, single-guide RNA; T_final, end time point; T_initial, start time point. H, Violin plots showing the log2 (fold-change) sgRNA enrichment (T_final over T_initial) in MV4;11 cells. Neg, negative controls, sgRNAs targeting known nonessential genes; Pos, positive controls, sgRNAs targeting known essential genes. Black lines denote median. See Supplementary Table S2. I, Scatter plot showing log2 (fold-change sgRNA enrichment) in MV4;11 in TDI-11055 vs. DMSO comparison. sgRNAs are positioned along the x axis by the ENL coding sequence. Data represent average across three replicate transductions. Regions 1 and 2 (R1 and R2) highlighted in blue contain 4 or more enriched sgRNAs. See Supplementary Table S3. sgENL326 shows the strongest enrichment in TDI-11055 treatment condition over DMSO among all sgRNAs. (continued on next page)
Constitutive Cas9 Vectors, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lenticas9+blast+vector/10__1158_slash_2159___8290__cd___21___1307-467-0-9?v=Addgene+inc
Average 96 stars, based on 1 article reviews
constitutive cas9 vectors - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier
wt cas9 expression plasmid lenticas9 puro  (Addgene inc)
95
Addgene inc wt cas9 expression plasmid lenticas9 puro
Figure 2. TDI-11055 suppresses the cellular growth of MLL-r and NPM1-mutated leukemia cells through on-target inhibition of ENL. A and B, Dose– response viability curves (8 days) for TDI-11055 in human leukemia cell lines with high (A) and low (B) dependence on ENL defined by genetic studies. n = 3. NPM1 mut, NPM1-mutated. C–F, Representative images (left) and quantification (right) of colonies formed by indicated human leukemia cell lines treated with DMSO or TDI-11055 (TDI; 1 and 10 μmol/L). Error bars represent mean ± SEM (n = 3). One of two independent experiment batches is shown. G, Schematic of <t>CRISPR-Cas9</t> mutagenesis scanning workflow. MOI, multiplicity of infection; sgRNA, single-guide RNA; T_final, end time point; T_initial, start time point. H, Violin plots showing the log2 (fold-change) sgRNA enrichment (T_final over T_initial) in MV4;11 cells. Neg, negative controls, sgRNAs targeting known nonessential genes; Pos, positive controls, sgRNAs targeting known essential genes. Black lines denote median. See Supplementary Table S2. I, Scatter plot showing log2 (fold-change sgRNA enrichment) in MV4;11 in TDI-11055 vs. DMSO comparison. sgRNAs are positioned along the x axis by the ENL coding sequence. Data represent average across three replicate transductions. Regions 1 and 2 (R1 and R2) highlighted in blue contain 4 or more enriched sgRNAs. See Supplementary Table S3. sgENL326 shows the strongest enrichment in TDI-11055 treatment condition over DMSO among all sgRNAs. (continued on next page)
Wt Cas9 Expression Plasmid Lenticas9 Puro, supplied by Addgene inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lenticas9+blast+vector/bio_rxiv__2023__03__16__532856-128-0-19?v=Addgene+inc
Average 95 stars, based on 1 article reviews
wt cas9 expression plasmid lenticas9 puro - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier
lenticas9 blast  (Addgene inc)
96
Addgene inc lenticas9 blast
Figure 2. TDI-11055 suppresses the cellular growth of MLL-r and NPM1-mutated leukemia cells through on-target inhibition of ENL. A and B, Dose– response viability curves (8 days) for TDI-11055 in human leukemia cell lines with high (A) and low (B) dependence on ENL defined by genetic studies. n = 3. NPM1 mut, NPM1-mutated. C–F, Representative images (left) and quantification (right) of colonies formed by indicated human leukemia cell lines treated with DMSO or TDI-11055 (TDI; 1 and 10 μmol/L). Error bars represent mean ± SEM (n = 3). One of two independent experiment batches is shown. G, Schematic of <t>CRISPR-Cas9</t> mutagenesis scanning workflow. MOI, multiplicity of infection; sgRNA, single-guide RNA; T_final, end time point; T_initial, start time point. H, Violin plots showing the log2 (fold-change) sgRNA enrichment (T_final over T_initial) in MV4;11 cells. Neg, negative controls, sgRNAs targeting known nonessential genes; Pos, positive controls, sgRNAs targeting known essential genes. Black lines denote median. See Supplementary Table S2. I, Scatter plot showing log2 (fold-change sgRNA enrichment) in MV4;11 in TDI-11055 vs. DMSO comparison. sgRNAs are positioned along the x axis by the ENL coding sequence. Data represent average across three replicate transductions. Regions 1 and 2 (R1 and R2) highlighted in blue contain 4 or more enriched sgRNAs. See Supplementary Table S3. sgENL326 shows the strongest enrichment in TDI-11055 treatment condition over DMSO among all sgRNAs. (continued on next page)
Lenticas9 Blast, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lenticas9+blast+vector/pmc06162433-80-17-18?v=Addgene+inc
Average 96 stars, based on 1 article reviews
lenticas9 blast - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier
lentiviral vectors  (Addgene inc)
97
Addgene inc lentiviral vectors
Figure 2. TDI-11055 suppresses the cellular growth of MLL-r and NPM1-mutated leukemia cells through on-target inhibition of ENL. A and B, Dose– response viability curves (8 days) for TDI-11055 in human leukemia cell lines with high (A) and low (B) dependence on ENL defined by genetic studies. n = 3. NPM1 mut, NPM1-mutated. C–F, Representative images (left) and quantification (right) of colonies formed by indicated human leukemia cell lines treated with DMSO or TDI-11055 (TDI; 1 and 10 μmol/L). Error bars represent mean ± SEM (n = 3). One of two independent experiment batches is shown. G, Schematic of <t>CRISPR-Cas9</t> mutagenesis scanning workflow. MOI, multiplicity of infection; sgRNA, single-guide RNA; T_final, end time point; T_initial, start time point. H, Violin plots showing the log2 (fold-change) sgRNA enrichment (T_final over T_initial) in MV4;11 cells. Neg, negative controls, sgRNAs targeting known nonessential genes; Pos, positive controls, sgRNAs targeting known essential genes. Black lines denote median. See Supplementary Table S2. I, Scatter plot showing log2 (fold-change sgRNA enrichment) in MV4;11 in TDI-11055 vs. DMSO comparison. sgRNAs are positioned along the x axis by the ENL coding sequence. Data represent average across three replicate transductions. Regions 1 and 2 (R1 and R2) highlighted in blue contain 4 or more enriched sgRNAs. See Supplementary Table S3. sgENL326 shows the strongest enrichment in TDI-11055 treatment condition over DMSO among all sgRNAs. (continued on next page)
Lentiviral Vectors, supplied by Addgene inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lenticas9+blast+vector/pmc11866496-493-0-10?v=Addgene+inc
Average 97 stars, based on 1 article reviews
lentiviral vectors - by Bioz Stars, 2026-08
97/100 stars
  Buy from Supplier

Image Search Results


Figure 2. TDI-11055 suppresses the cellular growth of MLL-r and NPM1-mutated leukemia cells through on-target inhibition of ENL. A and B, Dose– response viability curves (8 days) for TDI-11055 in human leukemia cell lines with high (A) and low (B) dependence on ENL defined by genetic studies. n = 3. NPM1 mut, NPM1-mutated. C–F, Representative images (left) and quantification (right) of colonies formed by indicated human leukemia cell lines treated with DMSO or TDI-11055 (TDI; 1 and 10 μmol/L). Error bars represent mean ± SEM (n = 3). One of two independent experiment batches is shown. G, Schematic of CRISPR-Cas9 mutagenesis scanning workflow. MOI, multiplicity of infection; sgRNA, single-guide RNA; T_final, end time point; T_initial, start time point. H, Violin plots showing the log2 (fold-change) sgRNA enrichment (T_final over T_initial) in MV4;11 cells. Neg, negative controls, sgRNAs targeting known nonessential genes; Pos, positive controls, sgRNAs targeting known essential genes. Black lines denote median. See Supplementary Table S2. I, Scatter plot showing log2 (fold-change sgRNA enrichment) in MV4;11 in TDI-11055 vs. DMSO comparison. sgRNAs are positioned along the x axis by the ENL coding sequence. Data represent average across three replicate transductions. Regions 1 and 2 (R1 and R2) highlighted in blue contain 4 or more enriched sgRNAs. See Supplementary Table S3. sgENL326 shows the strongest enrichment in TDI-11055 treatment condition over DMSO among all sgRNAs. (continued on next page)

Journal: Cancer Discovery

Article Title: Small-Molecule Inhibition of the Acyl-Lysine Reader ENL as a Strategy against Acute Myeloid Leukemia

doi: 10.1158/2159-8290.cd-21-1307

Figure Lengend Snippet: Figure 2. TDI-11055 suppresses the cellular growth of MLL-r and NPM1-mutated leukemia cells through on-target inhibition of ENL. A and B, Dose– response viability curves (8 days) for TDI-11055 in human leukemia cell lines with high (A) and low (B) dependence on ENL defined by genetic studies. n = 3. NPM1 mut, NPM1-mutated. C–F, Representative images (left) and quantification (right) of colonies formed by indicated human leukemia cell lines treated with DMSO or TDI-11055 (TDI; 1 and 10 μmol/L). Error bars represent mean ± SEM (n = 3). One of two independent experiment batches is shown. G, Schematic of CRISPR-Cas9 mutagenesis scanning workflow. MOI, multiplicity of infection; sgRNA, single-guide RNA; T_final, end time point; T_initial, start time point. H, Violin plots showing the log2 (fold-change) sgRNA enrichment (T_final over T_initial) in MV4;11 cells. Neg, negative controls, sgRNAs targeting known nonessential genes; Pos, positive controls, sgRNAs targeting known essential genes. Black lines denote median. See Supplementary Table S2. I, Scatter plot showing log2 (fold-change sgRNA enrichment) in MV4;11 in TDI-11055 vs. DMSO comparison. sgRNAs are positioned along the x axis by the ENL coding sequence. Data represent average across three replicate transductions. Regions 1 and 2 (R1 and R2) highlighted in blue contain 4 or more enriched sgRNAs. See Supplementary Table S3. sgENL326 shows the strongest enrichment in TDI-11055 treatment condition over DMSO among all sgRNAs. (continued on next page)

Article Snippet: Constitutive Cas9 vectors (LentiV_Cas9_Puro vector, ref. 80; LentiCas9_Blast vector, Addgene 52962, ref. 81; a gift from Feng Zhang, Massachusetts Institute of Technology, Cambridge, MA) were used to generate Cas9expressing cells. sgRNAs were cloned into the LRG2.1T (82).

Techniques: Inhibition, CRISPR, Mutagenesis, Infection, Comparison, Sequencing